SB treatment was also associated with decreases in the expression of RORγt, a marker of pro-inflammatory Th17 cells responsible for producing inflammatory factors such as IL-6 and IL-17, both of which were decreased in samples from SB-treated DM model animals. This evidence concerns the gene IL17A and diabetes mellitus.